Thymoma · 5 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
VIP Variant #01 | — | R 13 835 | 21d | — | — | ~4 | ~R 55 342 indirect | — |
Cisplatin and Etoposide (EP) Variant #22 | — | R 1 819 | 21d | ~5.0 mo | ~10.0 mo | ~4 | ~R 7 277 PFS proxy · indirect | 11 |
CISCA Variant #02 | — | R 1 258 | 21d | — | — | ~6 | ~R 7 550 indirect | — |
ADOC Variant #01 | — | R 1 084 | 28d | — | — | ~2 | ~R 2 167 indirect | — |
Carboplatin and Paclitaxel (CP) Variant #02 | — | R 1 025 | 21d | ~5.4 mo | ~11.0 mo | ~12 | ~R 12 296 PFS proxy · indirect | 57 |
5 of 5 regimens shown